We are investigating the fairness of the $71.00 per share in cash pursuant to which Axonics, Inc. (Nasdaq: AXNX) (“Axonics”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”). The sales price is below the price target of multiple Wall Street analysts.
If you remain an Axonics shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On January 8, 2024, Axonics announced that it had agreed to be sold for $71.00 per share in cash to Boston Scientific.
“We are investigating whether the Axonics Board of Directors acted in the best interests of Axonics shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Axonics shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”
Notably, according to TipRanks, the sales price of $71.00 per share is below the price target of multiple Wall Street analysts, including Wells Fargo: $77.00; Morgan Stanley: $76.00; Mizuho Securities: $75.00; Bank of America Securities: $75.00; Piper Sandler: $75.00; C.L. King: $75.00; and Truist Financial: $73.00.